Bottom Line Up Front: VA rates psoriasis under Diagnostic Code 7816 from 0% to 60%, based on either total body surface area (TBSA) affected or systemic therapy use. Here is the part most veterans miss: if you take any biologic injection or oral immunosuppressant year-round, you likely qualify for 60% based on treatment alone — regardless of how much skin is currently visible. And if your psoriasis has progressed to psoriatic arthritis, you can file for a separate rating under DC 5002 for your joints — that is not pyramiding, because skin and joint impairments are different body systems.

In This Article

DC 7816 Rating Criteria (0–60%)

Psoriasis is rated under 38 CFR § 4.118, Diagnostic Code 7816, using the General Rating Formula for the Skin. There are four rating tiers, determined by two factors: the percentage of your total body surface area (TBSA) affected and whether you require systemic therapy.

Rating TBSA Affected OR Systemic Therapy Requirement
60% More than 40% of entire body, or more than 40% of exposed areas Constant or near-constant systemic therapy (such as corticosteroids, biologics, or other immunosuppressive drugs) required during the past 12-month period
30% 20–40% of entire body, or 20–40% of exposed areas Systemic therapy (such as corticosteroids or other immunosuppressive drugs) required for a total duration of 6 weeks or more, but not constantly, during the past 12-month period
10% At least 5% but less than 20% of entire body, or at least 5% but less than 20% of exposed areas Intermittent systemic therapy (such as corticosteroids or other immunosuppressive drugs) required for a total duration of less than 6 weeks during the past 12-month period
0% Less than 5% of entire body and less than 5% of exposed areas No more than topical therapy required during the past 12-month period
Critical detail: The criteria use “OR” between TBSA and systemic therapy. You only need to meet one of the two columns to qualify for that rating tier. A veteran with 3% body coverage who takes a biologic injection monthly qualifies for 60% based on treatment alone.

Note that “exposed areas” refers to areas not normally covered by clothing — face, neck, hands, and forearms. For veterans with psoriasis concentrated on the scalp, face, or hands, this exposed-area measurement can produce a higher percentage than the total-body calculation.

TBSA Percentages and the Measurement Problem

The rating schedule hinges on total body surface area, but here is a problem most veterans do not know about: VA has no published methodology for calculating TBSA for skin condition ratings. There is no guidance in the Adjudication Procedures Manual specifying whether examiners should use the Rule of Nines, the Lund-Browder chart, the palm method (one palm equals approximately 1% BSA), or simple visual estimation.

This is not academic. The method chosen can shift your TBSA by several percentage points in either direction — enough to cross a rating threshold.

What this means for your claim: Do not leave TBSA measurement to chance. In your personal statement and at your C&P exam, specify your calculation method. For example: “Using the Rule of Nines, my psoriasis affects my bilateral lower extremities (36%) and trunk (18%), for a total of approximately 25% BSA.” Photographs with measurements are even stronger. If the examiner uses a different method that produces a lower number, you have a documented basis for dispute.

Psoriasis Fluctuates — Document Flares

Psoriasis is a waxing-and-waning condition. You might have 30% TBSA coverage during a flare and 8% during remission. If your C&P exam happens during a good period, the examiner may underestimate your severity.

The solution: maintain a photo log with dates. Photograph your skin during flares with a ruler or measuring tape for scale. These photos become evidence of your condition at its worst, not just the snapshot the examiner sees on exam day.

The Systemic Therapy Shortcut

This is the most underutilized pathway in psoriasis ratings. Under 38 CFR § 4.118(a), systemic therapy is defined as treatment administered through any route other than the skin — oral, injection, suppository, or intranasal. This includes:

Topical steroids are NOT systemic therapy. Creams, ointments, and topical solutions — even potent ones like clobetasol — are topical therapy regardless of how much of your body you apply them to. Only medications taken orally or by injection count as systemic therapy under the regulatory definition.

How Treatment Duration Maps to Ratings

Treatment Pattern Duration Rating
Monthly biologic injection year-round (e.g., Humira every 2 weeks) Constant/near-constant 60%
Methotrexate taken weekly, 8 months per year Near-constant (>6 weeks) 30% or 60%
Prednisone taper during severe flares, 3 courses of 2 weeks each 6 weeks total 30%
Single 4-week course of oral steroids <6 weeks 10%
Topical steroids only N/A (not systemic) 0%
The shortcut: If you are on a biologic injection for psoriasis — any biologic, at any frequency, year-round — you meet the “constant or near-constant systemic therapy” standard for 60%. Your TBSA becomes irrelevant. The evidence you need is pharmacy records showing continuous prescriptions over the past 12 months. Request a printout from your VA pharmacy or civilian pharmacy.

Documenting Systemic Therapy for Your Claim

VA has no formal policy on what evidence proves the duration of systemic therapy. Based on our review of BVA decisions and claims guidance, the strongest documentation includes:

  1. Pharmacy records showing fill dates, medication names, and quantities for each systemic medication over the past 12–24 months
  2. Prescription history from your treating dermatologist listing all systemic medications prescribed, with start and end dates
  3. Treatment logs if you receive infusions or injections at a clinic (e.g., Remicade infusion dates)
  4. A physician statement explicitly classifying your treatment as “systemic therapy” and confirming it has been continuous or near-continuous

Do not assume the C&P examiner will pull your pharmacy records. Bring them yourself and hand a copy to the examiner at the appointment.

Psoriatic Arthritis: The Separate DC 5002 Rating

Up to 30% of people with psoriasis develop psoriatic arthritis (PsA) — an inflammatory arthritis that attacks joints, tendons, and ligaments. Here is the part that most claims guidance misses entirely: psoriatic arthritis can be rated separately from psoriasis because they affect different body systems.

Psoriasis is a skin condition rated under 38 CFR § 4.118 (DC 7816). Psoriatic arthritis is a musculoskeletal condition that can be rated under 38 CFR § 4.71a, DC 5002 (rheumatoid arthritis), with ratings from 10% to 100%:

Rating DC 5002 Criteria (Active Process)
100% Constitutional manifestations associated with active joint involvement, totally incapacitating
60% Less than totally incapacitating, with weight loss and anemia productive of severe impairment, or severely incapacitating exacerbations occurring 4 or more times per year or a lesser number over prolonged periods
40% Symptom combinations productive of definite impairment of health, or incapacitating exacerbations occurring 3 or more times per year
20% One or two exacerbations per year in a well-established diagnosis
This is not pyramiding. Under 38 CFR § 4.14, pyramiding occurs when the same disability is rated under different diagnostic codes that evaluate the same manifestation. Psoriasis rates skin involvement. Psoriatic arthritis rates joint impairment. These are different functional impairments, so separate ratings are legally permissible — similar to how a veteran can receive separate ratings for eczema (skin) and asthma (respiratory) even if both involve immune dysfunction.

The Practical Hurdle

While the legal structure supports separate ratings, BVA decisions reveal a significant practical challenge. VA adjudicators frequently treat psoriasis and psoriatic arthritis as “inextricably intertwined” and remand cases for further development rather than granting separate ratings outright. This means veterans who pursue this pathway should be prepared for an appeal.

To maximize your chances:

Do not wait for PsA to develop. If you have service-connected psoriasis and begin experiencing joint pain, stiffness, swelling, or tendon pain (enthesitis), see a rheumatologist immediately and file a secondary claim. The earlier you establish the diagnosis, the stronger the claim for secondary service connection.

Secondary Conditions You Can Claim

Psoriasis is not just a skin disease. It is a systemic inflammatory condition associated with multiple comorbidities. Medical research confirms the following secondary conditions are linked to psoriasis, all of which are potentially claimable under 38 CFR § 3.310:

1. Psoriatic Arthritis (DC 5002)

The most direct secondary claim. Up to 30% of psoriasis patients develop PsA. As discussed above, this can be rated separately from 20% to 100% under the active process criteria.

2. Depression and Anxiety (DC 9434/9400)

The psychological burden of living with a visible, chronic skin condition is well-documented. Veterans with psoriasis on the face, hands, and other exposed areas experience social stigma, self-consciousness, and isolation. Mental health conditions secondary to psoriasis are rated under the General Rating Formula for Mental Disorders, from 0% to 100%.

3. Cardiovascular Disease and Hypertension

Psoriasis increases cardiovascular risk through chronic systemic inflammation. Research shows that moderate-to-severe psoriasis is an independent risk factor for heart disease, myocardial infarction, and stroke. Hypertension secondary to psoriasis can be rated under DC 7101 from 0% to 60%.

4. Metabolic Syndrome and Type 2 Diabetes

Veterans with psoriasis have higher rates of metabolic syndrome, insulin resistance, and type 2 diabetes. If you have service-connected psoriasis and develop diabetes, a nexus letter from an endocrinologist linking the systemic inflammation of psoriasis to metabolic dysfunction can support a secondary claim.

5. Obesity

While obesity itself is not a ratable condition, it can serve as an intermediate step to secondary conditions under Larson v. McDonough (2021, Fed. Cir.). If psoriasis limits physical activity due to pain or skin cracking, leading to weight gain, which in turn causes or aggravates sleep apnea or knee conditions, that chain of causation supports secondary claims for those end-point conditions.

Build the web. A veteran with service-connected psoriasis rated at 30% who also files successful secondary claims for psoriatic arthritis (40%), depression (30%), and hypertension (10%) could have a combined rating approaching 80%. Each secondary condition stacks through VA combined rating math, and the systemic nature of psoriasis creates multiple legitimate pathways.

Establishing Service Connection for Psoriasis

Service connection for psoriasis requires three elements:

  1. Current diagnosis: A dermatologist’s diagnosis of psoriasis (plaque, guttate, inverse, pustular, or erythrodermic)
  2. In-service event or occurrence: Either onset of psoriasis during service, or an in-service trigger such as physical trauma (Koebner phenomenon), severe stress, infection (strep throat can trigger guttate psoriasis), or exposure to chemicals or environmental hazards
  3. Nexus: A medical opinion connecting your current psoriasis to service

Direct Service Connection

If your service treatment records show treatment for a skin rash, scaling, or psoriasis-like symptoms during service, direct service connection is the strongest path. Even if the in-service records say “dermatitis” or “eczema,” a dermatologist can opine that those symptoms were early psoriasis that was misdiagnosed at the time.

Aggravation

If you had mild psoriasis before service and it worsened during service — due to stress, physical demands, or environmental exposure — you can claim aggravation under 38 CFR § 3.306. The key is showing that your condition got permanently worse beyond natural progression.

Presumptive Service Connection

Psoriasis is not on the standard presumptive condition lists. However, if you served in areas with herbicide exposure (Agent Orange) or burn pit exposure under the PACT Act, and you developed psoriasis, you may be able to argue that environmental exposure triggered or aggravated your autoimmune condition. This requires a strong nexus opinion and is more difficult, but not impossible.

C&P Exam Tips for Psoriasis

The C&P exam is where your rating is won or lost. Based on our review of BVA decisions and the regulatory framework, here is what matters:

1. Timing Matters

If possible, schedule your C&P exam during a flare. Psoriasis is rated on the severity the examiner observes, and a remission-phase exam will produce a lower TBSA measurement. If you cannot control timing, bring dated photos of your worst flares as supplementary evidence.

2. Bring Your Pharmacy Records

The examiner needs to document whether you use systemic therapy and for how long. Do not rely on the examiner pulling your records. Bring a complete printout of your medication history for the past 12–24 months, highlighting every systemic medication (biologics, oral immunosuppressants, oral steroids).

3. Know Your TBSA

Before the exam, estimate your own TBSA using the Rule of Nines or palm method. If the examiner records a lower number than your estimate, you can reference your calculation in a supplemental statement afterward.

The Rule of Nines for quick reference: Head/neck = 9%, each arm = 9%, chest = 9%, abdomen = 9%, upper back = 9%, lower back = 9%, each upper leg = 9%, each lower leg = 9%, groin = 1%. Your palm (not including fingers) is approximately 1% BSA.

4. Mention Every Area Affected

Do not just show the examiner your worst plaques. Mention every area where you have psoriasis — scalp, ears, nails, genitals, gluteal fold, skin creases. Many veterans have scalp psoriasis they do not think to show the examiner, or nail pitting they consider cosmetic. All of it counts toward TBSA.

5. Describe Impact on Daily Life

Tell the examiner how psoriasis affects your daily functioning: pain, itching, cracking and bleeding, difficulty sleeping, limited clothing choices, impact on work and social activities. This narrative supports the rating criteria and helps establish the basis for secondary mental health claims.

6. If You Have Joint Symptoms, Say So

If you have any joint pain, stiffness, or swelling, bring it up at the C&P exam. The examiner may note it in the report, which supports a separate claim for psoriatic arthritis. Do not assume joint symptoms will be captured in a skin exam — they will not unless you raise them.

Your Action Steps

  1. File an Intent to File (VA Form 21-0966) immediately to lock in your effective date while you gather evidence.
  2. Get a current dermatology diagnosis specifying the type of psoriasis and estimating your TBSA coverage at its worst. Ask your dermatologist to use the Rule of Nines in their notes.
  3. Pull your pharmacy records for the past 12–24 months. Highlight every systemic medication. If you are on a biologic or oral immunosuppressant year-round, this is your most direct path to 60%.
  4. Photograph your skin during flares with dates and a ruler for scale. Create a log covering at least 6–12 months to show the waxing-and-waning pattern and your worst coverage.
  5. If you have joint pain: see a rheumatologist and request a psoriatic arthritis evaluation. If diagnosed, file a separate secondary claim for PsA linked to service-connected psoriasis. Get a nexus letter distinguishing skin from joint impairment.
  6. Screen for secondary conditions. If you have depression, anxiety, hypertension, diabetes, or cardiovascular issues, discuss with your doctor whether psoriasis could be a contributing factor. File secondary claims for each.
  7. At your C&P exam: bring pharmacy records, flare photos, and your own TBSA estimate. Mention every affected body area, including scalp, nails, and skin folds. Describe functional impact.
  8. After your rating decision: review the coding sheet. Verify that systemic therapy duration was correctly documented. If your biologic use was overlooked or your TBSA was underestimated, file a Higher-Level Review.
  9. If denied separate PsA rating: appeal to the BVA, citing 38 CFR § 4.14 and distinguishing skin impairment (DC 7816) from joint impairment (DC 5002) as different functional limitations in different body systems.

Not Sure Where to Start With Your Psoriasis Claim?

VetAid’s AI analysis engine reviews your case documents and identifies the rating criteria, secondary conditions, and claim strategy specific to your situation.

Analyze My Case Free

Frequently Asked Questions

What is the VA rating for psoriasis?

VA rates psoriasis under Diagnostic Code 7816 using the General Rating Formula for the Skin. Ratings are 0%, 10%, 30%, or 60%, based on the percentage of total body surface area (TBSA) affected and whether you require systemic therapy. If you take a biologic injection or oral immunosuppressant year-round, you likely qualify for 60% based on treatment alone, regardless of visible skin coverage. The key evidence is pharmacy records documenting continuous systemic therapy over the past 12 months.

Can I get separate ratings for psoriasis and psoriatic arthritis?

Yes, it is legally permissible because psoriasis (skin, DC 7816) and psoriatic arthritis (joints, DC 5002) affect different body systems and are not the same functional impairment under 38 CFR § 4.14. However, VA adjudicators frequently treat the two as “inextricably intertwined” and remand rather than granting separate ratings outright. To succeed, file PsA as a separate secondary claim, get a rheumatologist nexus letter distinguishing skin from joint impairment, and be prepared to appeal if initially denied. The regulatory structure supports separate ratings even if adjudicator practice creates a hurdle.

Does systemic therapy qualify for 60%?

Yes, but the threshold is “constant or near-constant systemic therapy” during the past 12-month period. Under 38 CFR § 4.118(a), systemic therapy includes any medication administered by a route other than the skin — oral pills, injections, infusions, and suppositories. Veterans receiving biologic injections (Humira, Enbrel, Stelara, etc.) on a continuous schedule meet this standard. Veterans on intermittent systemic therapy totaling 6 or more weeks per year qualify for 30%. Less than 6 weeks of systemic therapy qualifies for 10%. Pharmacy records are the critical evidence.

What secondary conditions can I claim with psoriasis?

The strongest secondary claims from service-connected psoriasis are psoriatic arthritis (DC 5002, 20–100%), depression and anxiety (psychological burden of chronic visible skin disease), cardiovascular disease and hypertension (chronic systemic inflammation increases cardiovascular risk), and metabolic syndrome or type 2 diabetes. Medical research confirms these associations. Each secondary condition requires a nexus letter from a specialist linking it to your service-connected psoriasis. Obesity can serve as an intermediate step to downstream conditions under Larson v. McDonough.

Legal References